The goal of this research is to formulate and optimize an immediate-release capsule dosage form to control emotional and somatic factors in GI disorders. The prevalence of anxiety-related peptic ulcers and irritable bowel syndrome (IBS) is rising quickly in the current period, necessitating the urgent development of a novel combination to safely and effectively treat both conditions. In light of this, it was decided to combine two medications and formulate a capsule dosage form